Latest Regulatory Filings News

BirdDog Technology reported a slight 4.1% decline in Q3 FY25 sales to A$3.6 million while progressing strongly on its next-generation product roadmap and implementing significant cost reductions.

Arafura Rare Earths has marked a pivotal quarter with a A$200 million cornerstone equity commitment for its Nolans Project, alongside binding offtake agreements securing two-thirds of its NdPr oxide target amid rising rare earth demand and geopolitical tensions.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Antipa Minerals has consolidated its Paterson Province tenements into the expansive Minyari Project, resumed full ownership of Wilki and Paterson Projects following partner withdrawals, and launched a major drilling campaign targeting resource growth and new discoveries.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

Magnetite Mines has submitted a key Mining Lease Proposal for its Razorback Iron Ore Project and is progressing strategic funding agreements, including a $7 million convertible note facility. The company also filed a provisional patent for a novel saline water processing method, underscoring its technical innovation in green iron production.

Boss Energy Limited reported a solid first quarter for 2025, posting positive net cash from operating activities and maintaining robust cash reserves despite ongoing investing outflows.

Newmont Corporation’s 2024 Annual Report reveals a robust financial performance fueled by higher metal prices and the strategic acquisition of Newcrest Mining. The company also embarks on a major portfolio reshaping with planned divestitures of six non-core assets.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Far Northern Resources has amended its December 2024 Appendix 5B cash flow report to provide clearer details on investing activities, revealing a net cash outflow and a modest cash balance at quarter-end.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.